10th European Tay-Sachs and Sandhoff Family Conference
The 10th European Tay-Sachs and Sandhoff Family Conference was held on the 29 – 30 November via the…
Read More
The GGGA is working together to provide a global level of support for the GM1 and GM2 community.
Working together the GGGA members are supporting the GM1 and GM2 community.
Collectively the GGGA members are working to find a cure for these devastating diseases.
The GGGA consists of advocacy groups from all over the world who are supporting the GM1 and GM2 community.
Working together globally the GGGA has a remit to ensure that the GM1 and GM2 community have a constant level of care and access to therapies.
The GGGA is recognised as a collaborative group of advocacy leaders who work to ensure support of the community.
The members of the GGGA are from all over the world who support both the GM1 and GM2 community. You can see all of the members listed below and they can be contacted directly.
Together, the GGGA is committed to ensuring that the GM1 and GM2 community has access to information, study updates and a unified support network. By working globally, the GGGA can achieve its mission and bringing health equity to all families.
We want all families impacted by GM1 and GM2 to have access to information about the diseases so that they are empowered to manage and provide care.
We want to provide a global support network for the GM1 and GM2 community so that they are able to support each other as they navigate the diseases.
We aim to ensure that the GM1 and GM2 community are involved in the latest research and studies into the diseases and are always kept update.
If you want to get in touch with the GGGA please click the contact us button below.
The GGGA team are all representatives of their advocacy organisations who support the GM1 and GM2 community. Each is a dedicated advocacy leader who has been leading the fight against these devastating diseases.
Information about the GGGA.
A key role at the GGGA is educating families about the conditions to ensure that they understand the impact and progression of the diseases. Short videos on GM1 and GM2 which have been developed are shown below.
27December
The 10th European Tay-Sachs and Sandhoff Family Conference was held on the 29 – 30 November via the…
Read More
22December
Azafaros’ Phase 2 RAINBOW study, evaluating nizubaglustatin GM2 and NPC patients, is now fully enrolled
Read More
07August
PHILADELPHIA, Aug. 07, 2023 (GLOBE NEWSWIRE) — Passage Bio, Inc. (Nasdaq: PASG), a clinical-stage genetic medicines company focused…
Read MoreThe contact the GGGA please click the button below. We aim to reply to your message within 48 hours.